Clinical Trial Update: A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating continuous intravenous infusion of Terameprocol (EM-1421) in patients with refractory solid tumors and lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Terameprocol (terameprocol)

Snippet

Sponsor: Erimos Pharmaceuticals | Conditions: Refractory Solid Tumors, Lymphoma | Phase 1 | Status: TERMINATED